Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Procedural Characteristics and Clinical Outcomes in Patients Undergoing Percutaneous Coronary Intervention for Left Main Trifurcation Disease: The EXCEL trial.

Kandzari DE, Gershlick AH, Serruys PW, Leon MB, Morice MC, Simonton CA, Lembo NJ, Mansour S, Sabaté M, Sabik JF 3rd, Kappetein AP, Dressler O, Stone GW.

EuroIntervention. 2019 Dec 3. pii: EIJ-D-19-00686. doi: 10.4244/EIJ-D-19-00686. [Epub ahead of print]

PMID:
31793882
2.

Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease.

Stone GW, Kappetein AP, Sabik JF, Pocock SJ, Morice MC, Puskas J, Kandzari DE, Karmpaliotis D, Brown WM 3rd, Lembo NJ, Banning A, Merkely B, Horkay F, Boonstra PW, van Boven AJ, Ungi I, Bogáts G, Mansour S, Noiseux N, Sabaté M, Pomar J, Hickey M, Gershlick A, Buszman PE, Bochenek A, Schampaert E, Pagé P, Modolo R, Gregson J, Simonton CA, Mehran R, Kosmidou I, Généreux P, Crowley A, Dressler O, Serruys PW; EXCEL Trial Investigators.

N Engl J Med. 2019 Nov 7;381(19):1820-1830. doi: 10.1056/NEJMoa1909406. Epub 2019 Sep 28.

PMID:
31562798
3.

Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up: A Systematic Meta-analysis and Individual Patient Data Pooled Study.

Stone GW, Kimura T, Gao R, Kereiakes DJ, Ellis SG, Onuma Y, Chevalier B, Simonton C, Dressler O, Crowley A, Ali ZA, Serruys PW.

JAMA Cardiol. 2019 Sep 27. doi: 10.1001/jamacardio.2019.4101. [Epub ahead of print]

PMID:
31561250
4.

Clinical Outcomes Before and After Complete Everolimus-Eluting Bioresorbable Scaffold Resorption: Five-Year Follow-Up From the ABSORB III Trial.

Kereiakes DJ, Ellis SG, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, Tan SH, Ediebah DE, Simonton C, Stone GW; ABSORB III Investigators.

Circulation. 2019 Dec 3;140(23):1895-1903. doi: 10.1161/CIRCULATIONAHA.119.042584. Epub 2019 Sep 25.

PMID:
31553222
5.

Bypass Surgery or Stenting for Left Main Coronary Artery Disease in Patients With Diabetes.

Milojevic M, Serruys PW, Sabik JF 3rd, Kandzari DE, Schampaert E, van Boven AJ, Horkay F, Ungi I, Mansour S, Banning AP, Taggart DP, Sabaté M, Gershlick AH, Bochenek A, Pomar J, Lembo NJ, Noiseux N, Puskas JD, Crowley A, Kosmidou I, Mehran R, Ben-Yehuda O, Généreux P, Pocock SJ, Simonton CA, Stone GW, Kappetein AP.

J Am Coll Cardiol. 2019 Apr 9;73(13):1616-1628. doi: 10.1016/j.jacc.2019.01.037.

PMID:
30947913
6.

Impact of large periprocedural myocardial infarction on mortality after percutaneous coronary intervention and coronary artery bypass grafting for left main disease: an analysis from the EXCEL trial.

Ben-Yehuda O, Chen S, Redfors B, McAndrew T, Crowley A, Kosmidou I, Kandzari DE, Puskas JD, Morice MC, Taggart DP, Leon MB, Lembo NJ, Brown WM, Simonton CA, Dressler O, Kappetein AP, Sabik JF, Serruys PW, Stone GW.

Eur Heart J. 2019 Jun 21;40(24):1930-1941. doi: 10.1093/eurheartj/ehz113.

PMID:
30919909
7.

Outcomes Among Patients Undergoing Distal Left Main Percutaneous Coronary Intervention.

Kandzari DE, Gershlick AH, Serruys PW, Leon MB, Morice MC, Simonton CA, Lembo NJ, Banning AP, Merkely B, van Boven AJ, Ungi I, Kappetein AP, Sabik JF 3rd, Généreux P, Dressler O, Stone GW.

Circ Cardiovasc Interv. 2018 Oct;11(10):e007007. doi: 10.1161/CIRCINTERVENTIONS.118.007007.

PMID:
30354633
8.

Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease: EXCEL Trial.

Giustino G, Mehran R, Serruys PW, Sabik JF 3rd, Milojevic M, Simonton CA, Puskas JD, Kandzari DE, Morice MC, Taggart DP, Gershlick AH, Généreux P, Zhang Z, McAndrew T, Redfors B, Ragosta M 3rd, Kron IL, Dressler O, Leon MB, Pocock SJ, Ben-Yehuda O, Kappetein AP, Stone GW.

J Am Coll Cardiol. 2018 Aug 14;72(7):754-765. doi: 10.1016/j.jacc.2018.05.057.

9.

Outcomes After Coronary Stenting or Bypass Surgery for Men and Women With Unprotected Left Main Disease: The EXCEL Trial.

Serruys PW, Cavalcante R, Collet C, Kappetein AP, Sabik JF 3rd, Banning AP, Taggart DP, Sabaté M, Pomar J, Boonstra PW, Lembo NJ, Onuma Y, Simonton CA, Morice MC, McAndrew T, Dressler O, Stone GW.

JACC Cardiovasc Interv. 2018 Jul 9;11(13):1234-1243. doi: 10.1016/j.jcin.2018.03.051.

10.

Sex disparities in acute myocardial infarction care and outcomes.

Gul B, Kozuma K, Haimi I, Zhao W, Simonton C, Ying SW, Buda A, Mehta S, Baumbach A, Lansky A.

Catheter Cardiovasc Interv. 2018 Nov 1;92(5):E341-E347. doi: 10.1002/ccd.27622. Epub 2018 May 10.

PMID:
29745453
11.

3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial.

Kereiakes DJ, Ellis SG, Metzger C, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW; ABSORB III Investigators.

J Am Coll Cardiol. 2017 Dec 12;70(23):2852-2862. doi: 10.1016/j.jacc.2017.10.010. Epub 2017 Oct 31.

12.

Quality-of-Life After Everolimus-Eluting Stents or Bypass Surgery for Left-Main Disease: Results From the EXCEL Trial.

Baron SJ, Chinnakondepalli K, Magnuson EA, Kandzari DE, Puskas JD, Ben-Yehuda O, van Es GA, Taggart DP, Morice MC, Lembo NJ, Brown WM 3rd, Banning A, Simonton CA, Kappetein AP, Sabik JF, Serruys PW, Stone GW, Cohen DJ; EXCEL Investigators.

J Am Coll Cardiol. 2017 Dec 26;70(25):3113-3122. doi: 10.1016/j.jacc.2017.10.036. Epub 2017 Oct 30.

13.

Three-Year Outcomes With the Absorb Bioresorbable Scaffold: Individual-Patient-Data Meta-Analysis From the ABSORB Randomized Trials.

Ali ZA, Gao R, Kimura T, Onuma Y, Kereiakes DJ, Ellis SG, Chevalier B, Vu MT, Zhang Z, Simonton CA, Serruys PW, Stone GW.

Circulation. 2018 Jan 30;137(5):464-479. doi: 10.1161/CIRCULATIONAHA.117.031843. Epub 2017 Oct 31.

PMID:
29089314
14.

Very Late Restenosis Following Bioresorbable Scaffold Implantation.

Okuno T, Yahagi K, Horiuchi Y, Aoki J, Simonton CA, Rapoza R, Saito S, Kimura T, Tanabe K.

JACC Cardiovasc Interv. 2017 Sep 25;10(18):e167-e169. doi: 10.1016/j.jcin.2017.06.015. Epub 2017 Aug 30. No abstract available.

15.

Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.

Stuckey TD, Kirtane AJ, Brodie BR, Witzenbichler B, Litherland C, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri EL Jr, Gurbel PA, Mehran R, Généreux P, Ben-Yehuda O, Simonton CA, Stone GW; ADAPT-DES Investigators.

JACC Cardiovasc Interv. 2017 Aug 28;10(16):1607-1617. doi: 10.1016/j.jcin.2017.05.059. Epub 2017 Aug 2.

16.

2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy.

Ali ZA, Serruys PW, Kimura T, Gao R, Ellis SG, Kereiakes DJ, Onuma Y, Simonton C, Zhang Z, Stone GW.

Lancet. 2017 Aug 19;390(10096):760-772. doi: 10.1016/S0140-6736(17)31470-8. Epub 2017 Jul 18. Review.

PMID:
28732815
17.

Biological effect of microengineered grooved stents on strut healing: a randomised OCT-based comparative study in humans.

Vesga B, Hernandez H, Higuera S, Gasior P, Echeveri D, Delgado JA, Dager A, Arana C, Simonton C, Maehara A, Palmaz J, Granada JF.

Open Heart. 2017 May 22;4(1):e000521. doi: 10.1136/openhrt-2016-000521. eCollection 2017. Erratum in: Open Heart. 2018 Apr 28;5(1):e000521corr1.

18.

Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease.

Stone GW, Sabik JF, Serruys PW, Simonton CA, Généreux P, Puskas J, Kandzari DE, Morice MC, Lembo N, Brown WM 3rd, Taggart DP, Banning A, Merkely B, Horkay F, Boonstra PW, van Boven AJ, Ungi I, Bogáts G, Mansour S, Noiseux N, Sabaté M, Pomar J, Hickey M, Gershlick A, Buszman P, Bochenek A, Schampaert E, Pagé P, Dressler O, Kosmidou I, Mehran R, Pocock SJ, Kappetein AP; EXCEL Trial Investigators.

N Engl J Med. 2016 Dec 8;375(23):2223-2235. Epub 2016 Oct 31. Erratum in: N Engl J Med. 2019 Oct 31;381(18):1789.

19.

Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial.

Onuma Y, Sotomi Y, Shiomi H, Ozaki Y, Namiki A, Yasuda S, Ueno T, Ando K, Furuya J, Igarashi K, Kozuma K, Tanabe K, Kusano H, Rapoza R, Popma JJ, Stone GW, Simonton C, Serruys PW, Kimura T.

EuroIntervention. 2016 Oct 20;12(9):1090-1101. doi: 10.4244/EIJY16M09_01.

20.

Design and rationale for a randomised comparison of everolimus-eluting stents and coronary artery bypass graft surgery in selected patients with left main coronary artery disease: the EXCEL trial.

Kappetein AP, Serruys PW, Sabik JF, Leon MB, Taggart DP, Morice MC, Gersh BJ, Pocock SJ, Cohen DJ, Wallentin L, Ben-Yehuda O, van Es GA, Simonton CA, Stone GW.

EuroIntervention. 2016 Sep 18;12(7):861-72. doi: 10.4244/EIJV12I7A141.

21.

Bioresorbable vascular scaffolds for the treatment of coronary artery disease: what have we learned from randomized-controlled clinical trials?

Rizik DG, Hermiller JB, Simonton CA, Klassen KJ, Kereiakes DJ.

Coron Artery Dis. 2017 Jan;28(1):77-89. Review.

PMID:
27561169
22.

Current practices of Asia-Pacific cardiologists in the utilization of bioresorbable scaffolds.

Chanana BB, Chandra P, Cheng JJ, Dick R, Gwon HC, Hiremath MS, Huan DQ, Jeamanukoolkit A, Jiang T, Kwok OH, Lim MCL, Low AF, Mathew R, Mathew SK, McClean D, Nakamura S, Nguyen M, Qiao S, Santoso T, Saxena S, Schultz C, Sengottuvelu G, Seth A, Simonton CA, Soo CS, Sudhir K, Tsai CT, Wasan U, Whelan A, Wong C, Yap YG.

Int J Cardiol. 2016 Nov 1;222:832-840. doi: 10.1016/j.ijcard.2016.07.273. Epub 2016 Aug 1.

PMID:
27522385
23.

Optimum technique to reduce risk of stent thrombosis - Authors' reply.

Stone GW, Gao R, Kimura T, Simonton C, Serruys PW.

Lancet. 2016 Jul 9;388(10040):127-8. doi: 10.1016/S0140-6736(16)30772-3. No abstract available.

PMID:
27411875
24.

Bioresorbable scaffold - A magic bullet for the treatment of coronary artery disease?

Brie D, Penson P, Serban MC, Toth PP, Simonton C, Serruys PW, Banach M.

Int J Cardiol. 2016 Jul 15;215:47-59. doi: 10.1016/j.ijcard.2016.04.027. Epub 2016 Apr 12. Review.

PMID:
27111160
25.

Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.

Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW; ABSORB III Investigators.

N Engl J Med. 2015 Nov 12;373(20):1905-15. doi: 10.1056/NEJMoa1509038. Epub 2015 Oct 12.

26.

Feasibility of 320-row multi-detector computed tomography angiography to assess bioabsorbable everolimus-eluting vascular scaffolds.

Asami M, Aoki J, Serruys PW, Abizaid A, Saito S, Onuma Y, Kimura T, Simonton CA, Tanabe K.

Cardiovasc Interv Ther. 2016 Apr;31(2):96-100. doi: 10.1007/s12928-015-0353-1. Epub 2015 Oct 7.

PMID:
26445951
27.

Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.

Généreux P, Rutledge DR, Palmerini T, Caixeta A, Kedhi E, Hermiller JB, Wang J, Krucoff MW, Jones-McMeans J, Sudhir K, Simonton CA, Serruys PW, Stone GW.

Circ Cardiovasc Interv. 2015 May;8(5). pii: e001362. doi: 10.1161/CIRCINTERVENTIONS.114.001362.

PMID:
25940520
28.

Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: prospective validation of the SYNTAX Score II.

Campos CM, van Klaveren D, Farooq V, Simonton CA, Kappetein AP, Sabik JF 3rd, Steyerberg EW, Stone GW, Serruys PW; EXCEL Trial Investigators.

Eur Heart J. 2015 May 21;36(20):1231-41. doi: 10.1093/eurheartj/ehu518. Epub 2015 Jan 12.

PMID:
25583761
29.

Long-term clinical outcomes after everolimus- and sirolimus-eluting coronary stent implantation: final 3-year follow-up of the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial.

Shiomi H, Kozuma K, Morimoto T, Igarashi K, Kadota K, Tanabe K, Morino Y, Akasaka T, Abe M, Suwa S, Muramatsu T, Kobayashi M, Dai K, Nakao K, Uematsu M, Tarutani Y, Fujii K, Simonton CA, Kimura T; RESET Investigators.

Circ Cardiovasc Interv. 2014 Jun;7(3):343-54. doi: 10.1161/CIRCINTERVENTIONS.113.001322. Epub 2014 May 6.

PMID:
24803436
30.

Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial.

Brener SJ, Kereiakes DJ, Simonton CA, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Smith RS Jr, Ying SW, Cutlip DE, Stone GW.

Am Heart J. 2013 Dec;166(6):1035-42. doi: 10.1016/j.ahj.2013.08.030. Epub 2013 Oct 31.

PMID:
24268218
31.

Preclinical evaluation of second-generation everolimus- and zotarolimus-eluting coronary stents.

Yazdani SK, Sheehy A, Nakano M, Nakazawa G, Vorpahl M, Otsuka F, Donn RS, Perkins LE, Simonton CA, Kolodgie FD, Virmani R.

J Invasive Cardiol. 2013 Aug;25(8):383-90.

32.

Risk factors for coronary drug-eluting stent thrombosis: influence of procedural, patient, lesion, and stent related factors and dual antiplatelet therapy.

Sudhir K, Hermiller JB, Ferguson JM, Simonton CA.

ISRN Cardiol. 2013 Jun 23;2013:748736. doi: 10.1155/2013/748736. Print 2013.

33.

An evidence-based review of the impact of periprocedural myocardial infarction in carotid revascularization.

Stilp E, Baird C, Gray WA, Schneider PA, Simonton CA, Verta P, Mena-Hurtado CI.

Catheter Cardiovasc Interv. 2013 Nov 1;82(5):709-14. doi: 10.1002/ccd.25056. Epub 2013 Jul 19. Review.

PMID:
23765902
34.

Clinical outcomes in real-world patients with acute myocardial infarction receiving XIENCE V® everolimus-eluting stents: one-year results from the XIENCE V USA study.

Sudhir K, Hermiller JB, Naidu SS, Henry TD, Mao VW, Zhao W, Ferguson JM, Wang J, Jonnavithula L, Simonton CA, Rutledge DR, Krucoff MW; XIENCE V USA Investigators.

Catheter Cardiovasc Interv. 2013 Oct 1;82(4):E385-94. doi: 10.1002/ccd.24749. Epub 2013 Mar 28.

PMID:
23172848
35.

Can start-ups finish up?

Simonton CA.

Circ Cardiovasc Qual Outcomes. 2012 Nov;5(6):739-40. doi: 10.1161/CIRCOUTCOMES.112.968693. No abstract available.

PMID:
23170003
36.

Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials.

Kedhi E, Stone GW, Kereiakes DJ, Serruys PW, Parise H, Fahy M, Simonton CA, Sudhir K, Sood P, Smits PC.

EuroIntervention. 2012 Sep;8(5):599-606. doi: 10.4244/EIJV8I5A92.

37.

Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET).

Kimura T, Morimoto T, Natsuaki M, Shiomi H, Igarashi K, Kadota K, Tanabe K, Morino Y, Akasaka T, Takatsu Y, Nishikawa H, Yamamoto Y, Nakagawa Y, Hayashi Y, Iwabuchi M, Umeda H, Kawai K, Okada H, Kimura K, Simonton CA, Kozuma K; RESET Investigators.

Circulation. 2012 Sep 4;126(10):1225-36. Epub 2012 Jul 23.

PMID:
22824435
38.

Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study.

Naidu SS, Krucoff MW, Rutledge DR, Mao VW, Zhao W, Zheng Q, Wilburn O, Sudhir K, Simonton C, Hermiller JB.

JACC Cardiovasc Interv. 2012 Jun;5(6):626-35. doi: 10.1016/j.jcin.2012.02.014.

39.

Cost-effectiveness of everolimus- versus paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization (from the SPIRIT-IV Trial).

Amin AP, Reynolds MR, Lei Y, Magnuson EA, Vilain K, Durtschi AJ, Simonton CA, Stone GW, Cohen DJ.

Am J Cardiol. 2012 Sep 15;110(6):765-70. doi: 10.1016/j.amjcard.2012.05.006. Epub 2012 May 30.

PMID:
22651880
40.

Overview of the 2011 Food and Drug Administration Circulatory System Devices Panel meeting on the ACCULINK and ACCUNET Carotid Artery Stent System.

Gray WA, Simonton CA, Verta P.

Circulation. 2012 May 8;125(18):2256-64. doi: 10.1161/CIRCULATIONAHA.111.073486. No abstract available.

PMID:
22566349
41.

A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study).

Krucoff MW, Rutledge DR, Gruberg L, Jonnavithula L, Katopodis JN, Lombardi W, Mao VW, Sharma SK, Simonton CA, Tamboli HP, Wang J, Wilburn O, Zhao W, Sudhir K, Hermiller JB.

JACC Cardiovasc Interv. 2011 Dec;4(12):1298-309. doi: 10.1016/j.jcin.2011.08.010.

43.

Engineering assessment of the longitudinal compression behaviour of contemporary coronary stents.

Prabhu S, Schikorr T, Mahmoud T, Jacobs J, Potgieter A, Simonton C.

EuroIntervention. 2012 Jun 20;8(2):275-81. doi: 10.4244/EIJV8I2A42.

44.

Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial.

Stone GW, Rizvi A, Sudhir K, Newman W, Applegate RJ, Cannon LA, Maddux JT, Cutlip DE, Simonton CA, Sood P, Kereiakes DJ; SPIRIT IV Investigators.

J Am Coll Cardiol. 2011 Jun 28;58(1):19-25. doi: 10.1016/j.jacc.2011.02.022. Epub 2011 Apr 21.

45.

An integer based risk score for predicting 30-day major adverse cardiac or cerebrovascular events after percutaneous coronary intervention with drug-eluting stents: results from a large prospective multicentre registry, the STENT Group.

Ito H, Nussbaum M, Hermiller JB, Hodes Z, Brodie B, Cheek B, Juk S, Krainin F, Metzger C, Duffy P, Humphrey A, Laurent S, Simonton CA; STENT Group.

EuroIntervention. 2011 Mar;6(8):942-8. doi: 10.4244/EIJV6I8A164.

PMID:
21330241
46.

Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial).

Ng VG, Lansky AJ, Hermiller JB, Farhat N, Applegate RJ, Yaqub M, Sood P, Su X, Simonton CA, Sudhir K, Stone GW.

Am J Cardiol. 2011 Mar 15;107(6):841-8. doi: 10.1016/j.amjcard.2010.10.068. Epub 2011 Jan 20.

PMID:
21255760
47.

Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System).

Kereiakes DJ, Cutlip DE, Applegate RJ, Wang J, Yaqub M, Sood P, Su X, Su G, Farhat N, Rizvi A, Simonton CA, Sudhir K, Stone GW.

J Am Coll Cardiol. 2010 Dec 14;56(25):2084-9. doi: 10.1016/j.jacc.2010.10.006.

48.

Clinical and angiographic risk assessment in patients with left main stem lesions.

Garg S, Stone GW, Kappetein AP, Sabik JF 3rd, Simonton C, Serruys PW.

JACC Cardiovasc Interv. 2010 Sep;3(9):891-901. doi: 10.1016/j.jcin.2010.06.016. Review.

49.

Evaluation of the effects of everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches: 2-year results from the SPIRIT III randomized trial.

Applegate R, Hermiller J, Williams J, Gordon P, Doostzadeh J, Cao S, Su X, Sudhir K, Lansky A, Simonton C, Stone G.

Catheter Cardiovasc Interv. 2010 Nov 1;76(5):644-51. doi: 10.1002/ccd.22606.

PMID:
20506356
50.

Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.

Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ; SPIRIT IV Investigators.

N Engl J Med. 2010 May 6;362(18):1663-74. doi: 10.1056/NEJMoa0910496.

Supplemental Content

Loading ...
Support Center